Drug evaluation

VirNext offers complete evaluation and characterization of the antiviral or proviral effect of specific compounds, both in vitro and in vivo. Molecules can be evaluated on a large panel of viral strains according to the customer’s specific needs.  

Biological supports

VirNext accomplishes complete evaluation of impact of your compounds at different levels of concentrations on various biological supports.

  • Adherent cells : various human and animal cell lines are available.
  • Reconstituted pulmonary epithelium: in vitro  3D reconstituted lung tissue from primary basal and epithelial cells for high fidelity virus/drug  evaluation, particularly in the case of respiratory viruses. 
  • Animal models: please contact us for more information.

Antiviral drug testing

Toxicity and antiviral activity evaluation of selected candidate compounds can be enhanced by combining classical laboratory and software-assisted assays.

  • Cytotoxicity
  • Antiviral drug screening
  • IC50/EC50/LD50
  • Drug combinations


Proviral drug testing

VirNext evaluates and characterizes the proviral activities of your compounds and proposes optimized production conditions to maximize virus yield, both in cell and embryonated egg-based systems of production.

 

Resistance tests

VirNext evaluates the potential emergence and temporal development of viral resistance to the specific drug of your choice.




Viral detection and characterization

  • Processing of biological complex samples in BSL-2 and BSL-3 facilities
  • Panviral detection assay (Influenza, RSV, Metapneumovirus, Picornavirus, Adenovirus, Coronavirus, Parainfluenza, MVM Parvovirus, Bocavirus) by molecular biology methods
  • Sanger and Next-generation sequencing